Nyxoah SA Ordinary Shares
NYXHNyxoah SA is a Belgian healthcare company specializing in innovative solutions for sleep-related disorders, particularly sleep apnea. The company develops neuromodulation devices designed to improve patient outcomes through minimally invasive procedures, focusing on innovative, patient-centric technologies for sleep disorder management.
Company News
Nyxoah launched its Genio® system in the Netherlands, performing first successful implants at OLVG West and Zuyderland hospitals, offering an alternative treatment for Obstructive Sleep Apnea (OSA) patients who cannot tolerate CPAP.
Nyxoah successfully launched its Genio® neurostimulation system for Obstructive Sleep Apnea treatment in the Netherlands, with first implantations at OLVG West and Zuyderland hospitals, offering patients an alternative to CPAP therapy.
Nyxoah announced CMS has increased Medicare reimbursement for its Genio hypoglossal nerve stimulation therapy by 48% for hospital outpatient departments and 58% for ambulatory surgery centers in 2026, which is expected to support broader therapy adoption.
Nyxoah announced a substantial Medicare reimbursement increase for its Genio® sleep apnea treatment in 2026, with hospital outpatient services reimbursement rising 48% to $45,000 and ambulatory surgery center reimbursement increasing 58% to $42,373.
Nyxoah secured $77 million in financing through a private placement, registered direct offering, and convertible bond to support U.S. commercialization of its Genio system for treating Obstructive Sleep Apnea (OSA).
